Nurtec ODT Minimum Approved Age
Nurtec ODT (rimegepant) is FDA-approved for use in adults only, with no established minimum age for pediatric use. The drug label explicitly states "Safety and effectiveness in pediatric patients have not been established" 1.
Current FDA Approval Status
The FDA has approved Nurtec ODT 75 mg orally disintegrating tablet exclusively for adult patients (≥18 years) for:
- Acute treatment of migraine with or without aura
- Preventive treatment of episodic migraine
Pediatric Development Program
While Nurtec ODT is not currently approved for children, a Phase 1 pharmacokinetic study has been completed in children aged 6 to <12 years 2. This study evaluated weight-adjusted dosing:
- Children 15-30 kg received 25 mg
- Children >30-50 kg received 50 mg
- Children >50 kg received 75 mg
The study demonstrated a favorable safety profile, though exposures in the lower weight groups were lower than adult exposures at 75 mg 2. These findings will inform future pediatric dose refinement studies.
Off-Label Use in Adolescents
A retrospective analysis of 12 adolescents (mean age 15.3 years) showed that rimegepant may be safe and effective for acute migraine treatment in this age group 3. In this series, 83% reported resolution or improvement of migraine attacks, with no adverse events reported. However, this represents off-label use and is not FDA-approved.
Clinical Implications
- For adults ≥18 years: Nurtec ODT 75 mg is approved and should be considered per standard indications
- For children and adolescents <18 years: Nurtec ODT is not approved; use would be off-label and should only be considered after failure of age-appropriate approved therapies, with informed consent regarding the lack of FDA approval in this population
The evidence suggests pediatric approval may be forthcoming as clinical trials progress, but currently no minimum age exists because the drug lacks any pediatric indication 1, 2.